Lupin Bets on Specialty Pharma in EMEA with New Leadership
Mumbai-based pharmaceutical company Lupin Limited has appointed Thierry Volle as President of its Europe, Middle-East & Africa (EMEA) operations. This strategic move signals Lupin’s ambition to transform from a generics-focused company into a significant player in the specialty pharmaceutical market within the region.
A Veteran at the Helm
Thierry Volle brings over 25 years of management experience to Lupin, having previously held leadership positions at Vifor Pharma, where he led EU & International business operations, and Wyeth. His expertise lies in building and growing specialty pharmaceutical businesses, with a strong focus on business development, integration, and product portfolio management. Volle will be based at Lupin’s European headquarters in Zug, Switzerland.
EMEA: A Key Growth Region
The EMEA region represents a crucial market for Lupin’s expansion plans. Vinita Gupta, Lupin’s Chief Executive Officer, emphasized that Volle’s knowledge and experience will be instrumental in achieving these goals. Lupin currently holds a significant position in several key therapeutic areas, including cardiovascular, diabetology, asthma, and anti-infectives, and is a global leader in anti-TB and cephalosporin segments.
The Shift Towards Specialty Pharmaceuticals
Lupin’s decision to invest heavily in specialty pharmaceuticals reflects a broader industry trend. Generics markets are becoming increasingly competitive, driving companies to seek higher-margin opportunities in specialized treatments. This transition requires a different set of capabilities, including strong research and development, regulatory expertise, and commercialization strategies tailored to specific patient populations.
Volle’s Background in Innovative Pharma
Thierry Volle’s prior experience in the innovative pharmaceutical sector is particularly relevant to Lupin’s strategic shift. His background suggests a focus on developing and launching novel products, rather than simply competing on price in the generics market. He has as well been associated with European pharmaceutical associations such as vips Switzerland and EFPIA, and is currently a board member of the European Generics Industry Association Medicines of Europe.
Lupin’s Global Footprint and Financial Performance
Lupin is currently the 6th largest and fastest-growing top 10 generics player in the US, with a 5.5% market share by prescriptions. The company also holds strong positions in Japan and South Africa. In the financial year ending March 31, 2015, Lupin reported a consolidated turnover of approximately $2.06 billion and a profit after tax of $393 million.
Frequently Asked Questions
What is Lupin’s primary focus in the EMEA region?
Lupin is focused on transforming its business from a generics company into a specialty pharma player in the EMEA region.
Who is Thierry Volle?
Thierry Volle is the newly appointed President of Lupin’s EMEA operations, bringing over 25 years of experience in the pharmaceutical industry.
Where will Thierry Volle be based?
Thierry Volle will be based at Lupin’s European headquarters in Zug, Switzerland.
What are Lupin’s key therapeutic areas?
Lupin is a significant player in cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective, and NSAID therapeutic areas.
What was Lupin’s financial performance in 2015?
Lupin’s consolidated turnover was approximately $2.06 billion, and profit after tax was $393 million.
Did you know? Lupin is the 3rd largest Indian pharmaceutical company by sales globally.
Explore more about Lupin’s leadership team and global operations on their official website.
